国家药监局药品和医疗器械审评检查3家分中心挂牌成立

Core Viewpoint - The establishment of regional centers for drug and medical device review and inspection by the National Medical Products Administration (NMPA) is a significant step towards enhancing regulatory reforms and promoting high-quality development in the pharmaceutical industry in China [1] Group 1: Establishment of Regional Centers - The NMPA has set up review and inspection centers in Beijing-Tianjin-Hebei, Central China, and Southwest China from September 21 to 24 [1] - These centers aim to support major regional development strategies, including the coordinated development of Beijing-Tianjin-Hebei, the rise of Central China, and the promotion of Western development [1] Group 2: Goals and Objectives - The NMPA emphasizes high-level planning, construction, and quality development for these centers to align with regional industry characteristics [1] - The focus will be on building a professional and skilled team of reviewers and inspectors to enhance the efficiency of the review and inspection process [1] Group 3: Impact on the Pharmaceutical Industry - The initiative is expected to inject strong momentum into the high-quality development of China's pharmaceutical industry [1] - It aims to meet the public's expectations for the quality and safety of drugs and medical devices, as well as for innovation [1]